Now showing items 1-2 of 2

    • From class waivers to precision medicine in paediatric oncology. 

      Pearson, ADJ; Pfister, SM; Baruchel, A; Bourquin, J-P; Casanova, M; Chesler, L; Doz, F; Eggert, A; Geoerger, B; Jones, DTW; Kearns, PR; Molenaar, JJ; Morland, B; Schleiermacher, G; Schulte, JH; Vormoor, J; Marshall, LV; Zwaan, CM; Vassal, G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium (2017-07)
      New drugs are crucially needed for children with cancer. The European Paediatric Regulation facilitates paediatric class waivers for drugs developed for diseases only occurring in adults. In this Review, we retrospectively ...
    • Molecular similarity considerations in the licensing of orphan drugs. 

      Franco, P; Porta, N; Holliday, JD; Willett, P (2017-02)
      The large costs associated with modern drug discovery mean that governments and regulatory bodies need to provide economic incentives to promote the development of orphan drugs (i.e., medicinal products that are designed ...